August 27, 2009 Arno Therapeutics Announces Dosing of First Patient in Phase I of AR-12, a PDK-1 Inhibitor Targeting the PI3K/Akt Pathway
July 23, 2009 Arno Therapeutics Announces Enrollment of First Patient in Phase II Study of AR-67 (formerly DB-67) in Patients with Myelodysplastic Syndrome
May 11, 2009 FDA Accepts Arno Therapeutics’ IND for AR-12 a PDK1 Inhibitor That Blocks the PI3K/Akt Pathway
November 3, 2008 Arno Therapeutics to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
September 3, 2008 Arno Therapeutics Announces Appointment of Roger G. Berlin, MD, as Chief Executive Officer and Director
August 14, 2008 Capricor Therapeutics Appoints Thomas Copmann, Ph.D. as Vice President of Regulatory Affairs and Drug Development
August 14, 2008 Arno Therapeutics Announces Appointment of Brian Lenz, CPA as Chief Financial Officer
June 5, 2008 Arno Therapeutics Completes $30.7 Million Financing, Recapitalization and 1-for-8 Reverse Stock Split
January 28, 2008 Arno Therapeutics Initiates Pharmacokinetic Study for Onapristone Following Regulatory Acceptance – Biotrial to Serve as Contract Research Organization for Paris-Based Trial
January 28, 2008 Arno Therapeutics Completes License Agreements for the Exclusive Rights to Novel, Targeted Cancer Compounds
